Open Access
Volume 9, Number 1, March 2019
Article Number 5
Number of page(s) 4
Published online 22 February 2019
  1. Oronsky B, Ma PC, Morgensztern D, Carter CA. Nothing But NET: A Review of Neuroendocrine Tumors and Carcinomas. Neoplasia. 2017; 19(12): 991–1002 [CrossRef] [Google Scholar]
  2. Taal BG, Visser O. Epidemiology of neuroendocrine tumours. Neuroendocrinology. 2004; 80 Suppl 1: 3–7 [CrossRef] [Google Scholar]
  3. Oberg KE. Gastrointestinal neuroendocrine tumors. Ann Oncol. 2010;21 Suppl 7:vii72–80 [CrossRef] [Google Scholar]
  4. Hori T, Yasuda T, Suzuki K, Kanamori M, Kimura T. Skeletal metastasis of carcinoid tumors: Two case reports and review of the literature. Oncol Lett. 2012; 3(5): 1105–8 [CrossRef] [PubMed] [Google Scholar]
  5. Van Loon K, Zhang L, Keiser J, Carrasco C, Glass K, Ramirez MT, et al. Bone metastases and skeletal-related events from neuroendocrine tumors. Endocr Connect. 2015; 4(1): 9–17 [CrossRef] [PubMed] [Google Scholar]
  6. Meijer WG, van der Veer E, Jager PL, van der Jagt EJ, Piers BA, Kema IP, et al. Bone metastases in carcinoid tumors: clinical features, imaging characteristics, and markers of bone metabolism. J Nucl Med. 2003; 44(2): 184–91 [PubMed] [Google Scholar]
  7. Yao JC, Hassan M, Phan A, Dagohoy C, Leary C, Mares JE, et al. One hundred years after “carcinoid”: epidemiology of and prognostic factors for neuroendocrine tumors in 35, 825 cases in the United States. J Clin Oncol. 2008; 26(18): 3063–72 [CrossRef] [PubMed] [Google Scholar]
  8. Arnold PM, Floyd HE, Anderson KK, Newell KL. Surgical management of carcinoid tumors metastatic to the spine: Report of three cases. Clin Neurol Neurosurg. 2010; 112(5): 443–5 [CrossRef] [PubMed] [Google Scholar]
  9. Padalkar P, Tow B. Predictors of survival in surgically treated patients of spinal metastasis. Indian J Orthop. 2011; 45(4): 307–13 [CrossRef] [PubMed] [Google Scholar]
  10. Delank KS, Wendtner C, Eich HT, Eysel P. The treatment of spinal metastases. Dtsch Arztebl Int. 2011; 108(5): 71–9; quiz 80 [PubMed] [Google Scholar]
  11. Iwasa S, Morizane C, Okusaka T, Ueno H, Ikeda M, Kondo S, et al. Cisplatin and etoposide as first-line chemotherapy for poorly differentiated neuroendocrine carcinoma of the hepatobiliary tract and pancreas. Jpn J Clin Oncol. 2010; 40(4): 313–8 [CrossRef] [PubMed] [Google Scholar]
  12. Fjällskog ML, Granberg DP, Welin SL, Eriksson C, Oberg KE, Janson ET, et al. Treatment with cisplatin and etoposide in patients with neuroendocrine tumors. Cancer. 2001;92(5):1101–7 [CrossRef] [PubMed] [Google Scholar]
  13. Patta A, Fakih M. First-line cisplatin plus etoposide in high-grade metastatic neuroendocrine tumors of colon and rectum (MCRC NET): review of 8 cases. Anticancer Res. 2011; 31(3): 975–8 [PubMed] [Google Scholar]
  14. Lee J, Choi J, Choi C, Seong J. Role of radiotherapy for pancreato-biliary neuroendocrine tumors. Radiat Oncol J. 2013; 31(3): 12530 [Google Scholar]
  15. Iwata T, Ueno H, Itami J, Ito Y, Inaba K, Morizane C, et al. Efficacy of radiotherapy for primary tumor in patients with unresectable pancreatic neuroendocrine tumors. Jpn J Clin Oncol. 2017; 47(9): 826–31 [CrossRef] [PubMed] [Google Scholar]